J Nucl Med. 2007; 48 (Supplement 2):364P
Oncology: Clinical Diagnosis-Solid Tumors
Clinical Diagnosis-Solid Tumors Posters |
Diagnostic and prognostic values of FDG-PET in patients with non-small cell lung cancer
Koichiro Abe1,
Hirofumi Koga1,
Koichiro Kaneko1,
Hirofumi Sawamoto1,
Hidetake Yabuuchi1,
Ichiro Yoshino2,
Masayuki Sasaki3 and
Hiroshi Honda1
1 Clinical Radiology; ;
2 Surgery and Science; ;
3 Health Sciences, Kyushu University, Fukuoka, Japan
1558
Objectives: Lung cancer is one of the leading causes of death in Japan as well as Western countries. Accurate diagnosis and staging are the most important factors for the selection of optimal treatment and the prediction of prognosis. The purpose of this study was to address the efficacy of FDG-PET for the staging and prognostic prediction in the patients with non-small cell lung cancer (NSCLC). Methods: Forty-four patients (26 males, 18 females) were analyzed in this study. Patients’ ages ranged from 36 to 82 years (mean 64 ± 11 years). The clinical stage of each patient was determined by imaging techniques, including chest radiography, contrast-enhanced CT of the chest and abdomen, and bone scintigraphy, with and without FDG-PET. All of patients were initially treated by surgery. Thirty-six patients had adenocarcinoma, 4 patients squamous cell carcinoma, 2 patients large cell carcinoma, 1 patient adenosquamous cell carcinoma and 1 patient sarcomatoid carcinoma. All patients were followed for at least 230 days after the surgery. Results: One patient was accurately upstaged and 3 patients were downstaged by adding the FDG-PET findings. N statuses correctly diagnosed in 3 of these patients by FDG-PET. The accuracy of diagnosis improved from 81.8 % to 90.9 % by adding the FDG-PET findings. Univariate analysis showed significant difference in disease-free survival for pTNM stage (
I vs. 
II) (p=0.0004), maximum diameter of primary tumor ( 25 mm vs. > 25 mm) (p=0.029), N statuses (N0 vs. N1) (p=0.0057), and standardized uptake values (SUVs) of primary tumors (< 3.5 vs. 3.5) (p<0.0001). Multivariate analysis indicated that SUV of the primary tumor was the most significant independent prognostic factor for disease-free survival (p=0.0073). Conclusions: The SUV values of primary tumors determined by FDG-PET closely correlated with disease-free survival in patients with NSCLC. FDG-PET proved to be a powerful tool not only for the correct diagnosis of cancer staging but also for the prognostic prediction in patients with NSCLC.
